Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis
Authors:
- Fatima SfifouFSFatima Sfifou
- Arbi EL BouaitiABArbi EL Bouaiti
Open Access
- 17 August 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 69, 102731
Abstract
Introduction: Glioblastomas are aggressive primary intracranial tumours of the central nervous system causing significant mortality and morbidity worldwide. Objective: This study aims to evaluate the prognostic value of tissue expression by immunostaining of hypoxiainducible factor (HIF-1 alpha), isocitrate dehydrogenase 1 (IDH1), and tumour protein p53 in glioblastoma in Moroccan patients. The association of HIF-1 alpha, IDH1, and p53 expression with the clinicopathological data and overall patient survival (OS) was also evaluated. Materials and methods: Confirmed glioblastomas were included in this study. Twenty-two tissue samples were obtained by neurosurgical intervention resulting from total resection, and subtotal resection or biopsy. Karnofsky index, histological type of tumour, and the status of IDH1, p53 protein, and HIF-1 alpha expression by immunostaining were reported. Results: The majority of the patients were males (64%) with a sex ratio of 1.75. The average age was 54 +/- 13. Median follow-up was 10.10 months and median overall survival was 10 months. The expression of HIF-1 alpha was high in 10 samples (45%) and low in 12 (55%). There was a statistically significant difference in OS of 85% at 12 months for the subgroup of patients "HIF-1 alpha negative IDH1 positive" p = 0.038, the unadjusted analysis showed that the group "HIF-1 alpha positive, IDH1 positive" was a poor prognostic factor, the HR was 0.08 (95% CI: 0.009-0.756, p = 0.027). Conclusion: Patients with negative HIF-1 alpha expression and positive IDH1 expression have a better prognosis, suggesting that these two biomarkers may be useful in the search for new approaches for targeted therapy in glioblastoma.Keywords
Funding Information
- Université Mohammed V de Rabat
This publication has 43 references indexed in Scilit:
- Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistryJournal of Translational Medicine, 2013
- Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implicationsExperimental Cell Research, 2012
- Clinical application of stem cell therapy in Parkinson's diseaseBMC Medicine, 2012
- Reciprocal influence of the p53 and the hypoxic pathwaysCell Death & Disease, 2011
- Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?Current Opinion in Genetics & Development, 2010
- Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implicationsBMC Cancer, 2009
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009
- Overexpression of Hypoxia-Inducible Factor 1α and p53 Is a Marker for an Unfavorable Prognosis in Gastric CancerClinical Cancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor proteinThe EMBO Journal, 2000